Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q2 FY27 results · Jul–Sep 2026
Solara Active Pharma Sciences reported revenue from operations of ₹417.34 crore (up 33.1% from Q2 FY26) and net profit of ₹28.46 crore for Q2 FY27 (Jul–Sep 2026), on a consolidated basis.
| Item | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 417.34 | 313.54 | +33.1% | 381.60 | +9.4% |
| Other income | 0.54 | 0.49 | +10.2% | 2.69 | −79.9% |
| Total income | 417.88 | 314.03 | +33.1% | 384.29 | +8.7% |
| Profit before tax | 28.46 | (10.10) | Turned profit | 16.31 | +74.5% |
| Net profit for the period | 28.46 | (10.10) | Turned profit | 16.31 | +74.5% |
| EPS, basic (₹) | 5.92 | (2.36) | Turned profit | 3.52 | +68.2% |
| Net margin (%) | 6.8 | -3.2 | 4.3 |
| Item | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 417.34 | 313.54 | +33.1% | 381.60 | +9.4% |
| Other income | 0.23 | 0.49 | −53.1% | 1.92 | −88.0% |
| Total income | 417.57 | 314.03 | +33.0% | 383.52 | +8.9% |
| Profit before tax | 29.61 | (10.08) | Turned profit | 16.99 | +74.3% |
| Net profit for the period | 29.61 | (10.08) | Turned profit | 16.99 | +74.3% |
| EPS, basic (₹) | 6.16 | (2.36) | Turned profit | 3.67 | +67.8% |
| Net margin (%) | 7.1 | -3.2 | 4.5 |
Consolidated
- Filed with BSE
- 16 Oct 2026, 17:58 IST
- Board meeting
- 16 Oct 2026
- Period
- 01 Jul 2026 to 30 Sep 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 16 Oct 2026, 17:58 IST
- Board meeting
- 16 Oct 2026
- Period
- 01 Jul 2026 to 30 Sep 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE